Profound and Telix enter co-education agreement for prostate cancer care
Profound Medical and Telix Pharmaceuticals entered a co-education agreement to advance PSMA-informed prostate care and expand access to TULSA-PRO. The collaboration aims to support appropriate patient selection and optimize treatment plans using complementary imaging and therapy technologies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed